Nothing Special   »   [go: up one dir, main page]

WO1984002911A1 - AGENTS ANTIBACTERIENS DE beta-LACTAME - Google Patents

AGENTS ANTIBACTERIENS DE beta-LACTAME Download PDF

Info

Publication number
WO1984002911A1
WO1984002911A1 PCT/GB1984/000010 GB8400010W WO8402911A1 WO 1984002911 A1 WO1984002911 A1 WO 1984002911A1 GB 8400010 W GB8400010 W GB 8400010W WO 8402911 A1 WO8402911 A1 WO 8402911A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
formula
compound
acid
alkyl
Prior art date
Application number
PCT/GB1984/000010
Other languages
English (en)
Inventor
Peter Henry Milner
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of WO1984002911A1 publication Critical patent/WO1984002911A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to a class of novel ⁇ -lactam derivatives, which have antibacterial activity and are of value in the treatment of infections in animals especially mammals including roan caused by a wide range of organisms, particularly Gram-negative organisms.
  • the invention also relates to a process for the preparation of such compounds, intermediates for use in the preparation of the compounds and to pharmaceutical compositions comprising the antibacterially active compounds.
  • R 1 and R 3 are independently an in vivo hydrolysable group, or R 1 and R 3 together form an in vivo hydrolysable group, provided that R 1 and R 3 are not both C 1-6 alkylcarbonyl;
  • R 7 is a hydroxyl, carboxylic acid group or lower alkyl or phenyl, tolyl or indanyl ester thereof, amino or a substituted amino group;
  • R 2 is hydrogen or a readily removable carboxyl protecting group; and Y is:
  • halogen unless otherwise defined is suitably fluorine, chlorine, bromine, and iodide, preferably chlorine and bromine.
  • carboxylic ester unless otherwise defined suitably includes C 1-6 alkyl esters.
  • acyloxy unless otherwise defined suitably includes C 1-6 alkylcarbonyloxy groups.
  • aryl unless otherwise defined suitably includes phenyl and naphthyl, preferably phenyl, optionally substituted with up to five halogen,
  • heterocyclyl unless otherwise defined suitably includes single or fused rings comprising up to four hetero atoms in the ring selected from oxygen, nitrogen and sulphur and optionally substituted with up to three halogen, C 1-6 alkyl, C 1-6 alkoxy, halo-(C 1-6 )-alkyl, hydroxy, amino, carboxy, C 1 _ 6 alkoxycarbonyl, C 1-6 alkoxycarbonyl (C 1-6 ) alkyl, aryl or oxo groups.
  • the group R 1 and R 3 may represent, for example C 1 _ 6 alkoxycarbonyl, such as methoxycarbonyl or ethoxycarbonyl.
  • R 1 and R 2 are the same group.
  • R 1 and R 3 When R 1 and R 3 are joined they may represent C 1-6 alkylene, in particular methylene or ethylene. When R 1 and R 3 together represent methylene, the substituent on the phenyl ring becomes -O.CH 2 .O-.
  • the compounds of the present invention may contain both an amino group and/or a carboxyl group and may, therefore, exist as the zwitterion or may form salts with suitable acids or bases.
  • the formamido group can exist in two preferred conformations, those wherein the hydrogen atoms of the -NH-CHO are, cis- or trans-, of which the cisconformation normally predominates.
  • Y is -S-C(CH 3 ) 2 -, -S-CH 2 -,
  • Q' represents hydrogen, halogen, hydroxy, mercapto, cyano, carboxy, carboxylic ester, C 1-4 alkyloxy, acyloxy or heterocyclylthio group.
  • a particularly preferred value for Y is -S-C(CH 3 ) 2 -.
  • Those compounds of the formula (I) wherein R 2 is a readily removable carboxyl protecting group or a nonpharmaceutically acceptable salt are primarily useful as intermediates in the preparation of compounds of the formula (I) wherein R 2 is a free carboxyl group or a pharmaceutically acceptable salt thereof. Also included within the readily removable carboxyl protecting groups R 2 are pharmaceutically acceptable in vivo hydrolysable ester groups. From the forgoing it will be realised that suitable antibacterially active compounds are those of formula (II) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
  • R 1 , R 3 , Y and R 7 are as defined with respect to formula (I).
  • the ⁇ -lactam antibiotic compounds of the present invention are intended for use in pharmaceutical compositions it will readily be understood that they are each provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutial compositions. Although the purity of intermediate compounds of the present invention is less critical it will readily be understood that the substantially pure form is preferred as for the ⁇ -lactam antibiotic compounds. Preferably, whenever possible, the compounds of the present invention are obtained in crystalline form.
  • Suitable pharmaceutically acceptable in vivo hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt.
  • Suitable ester groups of this type include those of part formula (i), (ii) and (iii):
  • R a is hydrogen, methyl, or phenyl
  • R b is C 1-6 alkyl, C 1-6 alkoxy or phenyl
  • R a and R b together form a 1,2-phenylene group optionally substituted by one or two methoxy groups
  • R c represents C 1- 6 alkylene optionally substituted with a methyl or ethyl group
  • R d and R e independently represent C 1-6 alkyl
  • R f represents C 1-6 alkyl.
  • suitable in vivo hydrolysable ester group include for example acyloxyalkyl groups such as acetoxymethyl, pivaloyloxymethyl, ⁇ -acetoxyethyl and ⁇ -pivaloyloxyethyl groups; alkoxycarbonyloxyalkyl groups, such as ethoxycarbonyloxymethyl and ⁇ -ethoxycarbonyloxyethyl; dialkylaminoalkyl especially di-loweralkylamino alkyl groups such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl; lactone groups such as phthalidyl and dimethoxyphthalidyl; and esters linked to a second ⁇ -lactam antibiotic or to a ⁇ -lactamase inhibitor.
  • acyloxyalkyl groups such as acetoxymethyl, pivaloyloxymethyl, ⁇ -acetoxyethyl and ⁇
  • Suitable readily removable carboxyl protecting groups for the group -CO 2 R 2 in formula (I) include ester derivatives of the carboxylic acid.
  • the derivative is preferably one which may readily be cleaved.
  • Suitable ester-forming carboxyl-protecting groups are those which may be removed under conventional conditions.
  • Such groups for R 2 include benzyl, p-methoxybenzyl, benzoylmethyl, p-nitrobenzyl, 4-pyridylmethyl, 2,2,2-trichloroethyl,
  • the carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular R 2 group, for example, acid - and base catalysed hydrolysis, or by enzymically -catalysed hydrolysis, or by hydrogenolysis.
  • Suitable pharmaceutically acceptable salts of the carboxy group of the compound of formula (I) include metal salts eg aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy-lower alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tris-(2-hydroxyethyl)amine, cycloalkylamines such as dicyclohexylamine, or with procaine, dibenzylamine, N,N'-dibenzylethylenediamine, 1-e ⁇ henamine, N-ethylpiperidine, N-benzyl- ⁇ phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, ethylenediamine, or bases of the pyridine type such as pyridine, collidine
  • Suitable salts include the lithium and silver salt.
  • Some of the compounds of this invention may be crystallised or recrystallised from solvents containing water. In such cases water of hydration may be formed.
  • This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
  • Suitable values for Q in the compounds of the formula (I) include the acetoxy, heterocyclylthio group, and nitrogen containing heterocyclic group bonded via nitrogen.
  • Q and Q' represent the acetoxy or heterocyclylthio group.
  • heterocyclylthio group may suitably be represented by the formula:
  • Het is a five or six membered heterocyclic ring containing from 1 to 4 atoms selected from N, O, and S unsubstituted or substituted with one or two groups selected from C 1-6 alkyl, C 1-6 alkoxy, hydroxyalkyl, C 1-6 alkenyl, alkoxyalkyl, carboxyalkyl, sulphonylalkyl, carbamoylalkyl, trifluoromethyl, hydroxy, halogen, oxo, (subst)aminoalkyl, and carboxyalkyl or two substituents may be linked to form the residue of a heterocyclic or carbocyclic ring.
  • Het examples include unsubstituted and substituted imidazolyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, thiatriazolyl, oxazolyl, triazinyl and oxadiazolyl.
  • Het include unsubstituted and substituted 1, 2, 3-triazolyl; 1, 2, 4-triazolyl; tetrazolyl; oxazolyl; thiazolyl; 1, 3, 4-oxadiazolyl; 1, 3, 4-thiadiazolyl, or 1, 2, 4-thiadiazolyl.
  • the heterocyclylthio group is 1-methyl-1H-tetrazol-5-ylthio, 2-methyl-1,3,4-thiadiazol-5-ylthio, 1-carboxymethyl-1H-tetrazol-5-ylthio or 6-hydroxy-2-methyl-5-oxo-2H-1,2,4-triazin-3-ylthio.
  • the nitrogen containing heterocyclic group bonded via nitrogen is suitably a pyridinium group unsubstituted or substituted with one or two groups selected from C 1-6 alkyl, C 1-6 alkoxy, hydroxyalkyl, C 1-6 alkenyl, alkoxyalkyl, carboxyalkyl, sulphonylalkyl, carbamoylmethyl, carbamoyl, trifluoromethyl, hydroxy, halogen, oxo, and aminoalkyl or two substituents-may-be linked to fossm the residue of a carbocyclic ring.
  • R 7 is a substituted amino group.
  • substituted amino group R 7 is a ureido, acylamino or acylureido group.
  • R 7 is of formula (III) :
  • R 9 is hydrogen or a C 1-6 alkyl group and R 10 is an optionally substituted 5- or 6- membered heterocyclic group containing one or two nitrogen heteroatoms; or R 9 and R 10 together with the nitrogen atom to which they are attached form an optionally substituted five- or six-membered heterocyclic group containing one or two nitrogen heteroatoms.
  • R 9 is hydrogen
  • Suitable substituents for the 5- or 6- membered heterocyclic group of R 10 or R 9 and R 10 together include the optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl group; optionally substituted phenyl, oxo; the hydroxy group optionally substituted by alkyl, alkenyl, cycloalkyl, phenyl, pyridyl, pyrimidyl or benzyl; the optionally substituted mercapto group, the alkylsulphonyl group; the substituted imino group; or the amino group optionally substituted by an alkyl, alkenyl, cycloalkyl, phenyl, substituted phenyl or benzyl group.
  • two substituents on the ring may form the residue of a further carbocyclic or heterocyclic ring.
  • the carbon atom marked * in formulae herein is asymmetric so that the compounds may exist as two optically active diastereoisomers.
  • prepared from the D-side chain exhibits the highest antibacterial activity and accordingly the D compound or the DL mixtures are preferred, with the D compound being particularly preferred.
  • Preferred compounds within formula (I) are the penicillin derivatives of formula (IV) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof:
  • R 1 and R 3 are as defined with respect to formula (I);
  • R 12 is hydrogen or C 1-6 alkyl and R 13 is an optionally substituted five- or six-membered heterocyclic group containing one or two nitrogen heteroatoms; or R 12 and R 13 together with the nitrogen atom to which they are attached form an optionally substituted five- or six-membered heterocyclic group containing one or two nitrogen heteroatoms.
  • Suitable substituents for the five- or sixmembered heterocyclic group of R 13 or R 12 and R 13 together include the alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl group, optionally substituted phenyl, oxo, the hydroxy group optionally substituted by alkyl, alkenyl, cycloalkyl, phenyl, pyridyl, pyrimidyl or benzyl, the optionally substituted mercapto group, the alkylsulphonyl group, the substituted imino group, or the amino group optionally substituted by an alkyl, alkenyl, cycloalkyl, phenyl, substituted phenyl or benzyl group.
  • two substituents on the ring may form the residue of a further carbocyclic or heterocyclic ring.
  • R 12 is hydrogen
  • One particularly preferred sub-rgroup within the present invention provides a compound of formula (V) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof:
  • R 14 represents hydrogen, C 1-6 alkyl, substituted alkyl, aryl, or aralkyl
  • R 15 and R 16 are the same or different and represent hydrogen, C 1-6 alkyl, substituted alkyl, halogen, amino, hydroxy or
  • Preferred compounds within formula (V) are the penicillin derivatives of formula (VI) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof:
  • R 1 , R 3 , R 14 , R 15 and R 16 are as hereinbefore defined.
  • Suitable C 1-6 alkyl groups for the groups R 14 , R 15 and R 16 in formula (V) and formula (VI) include methyl, ethyl, n- and iso-propyl, n, sec-, iso- and tert-butyl.
  • R 14 is ethyl.
  • R 15 and R 16 are hydrogen.
  • a further preferred subgroup of compounds within the present invention are the compounds of formula (VII) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof:
  • R 1 , R 3 and R 7 are as hereinbefore defined; Y 1 is oxygen or sulphur; and Q 2 represents acetyloxy, a group -SHet, wherein Het is as hereinbefore defined, or Q 2 represents a subgroup of formula (h) :
  • R q and R p may be the same or different and each represents hydrogen, C 1-6 alkyl, C 1-6 alkoxy, hydroxyalkyl, C 1-6 alkenyl, alkoxyalkyl, carboxyalkyl, sulphonylalkyl, carbamoylalkyl, carbamoyl, trifluoromethyl, hydroxy, halogen, and aminoalkyl or R q and R p together from the residue of a caroocyclic ring.
  • Suitable groups 'Het' within formula (VII) include substituted and unsubstituted 1,2,3-triazolyl; 1,2,4-triazolyl; tetrazolyl; oxazolyl; thiazolyl; 1,3,4-oxadiazolyl; 1,2,4-triazinyl; 1,3,4-thiadiazolyl or 1,2,4-thiadiazolyl.
  • the groups 'SHet' is 1-methyl-1H-tetrazol-5-ylthio, 2-methyl-1,3,4-thiadiazol-5-ylthio, 1-carboxymethyl-1H-tetrazol-5-ylthio or 6-hydroxy2-methyl-5-oxo-2H-1,2,4-triazin-3-ylthio.
  • R q represents hydrogen
  • R p represents hydrogen, sulphonylalkyl or carbamoyl, preferably the substituent R p is in the 4-position.
  • Y 1 is sulphur
  • Y 1 is oxygen
  • R 7 within formula (VII) is a subgroup of formula (j):
  • R 14 , R 15 and R 16 are as hereinbefore defined with reference to formula (V).
  • antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, according to techniques and procedures per se known in the art with reference to other antibiotics, and the invention therefore includes within its scope a pharmaceutical composition comprising an antibiotic compound according to the present invention such as, for example a compound of formula (II) above together with a pharmaceutically acceptable carrier or excipient.
  • compositions may be formulated for administration by any suitable route, such as oral or parenteral, or by topical application.
  • the compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth,or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine, tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters, glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia
  • Suppositories will contain conventional suppository base, eg cocoa-butter or other glyceride.
  • fluid unit dosage forms are prepared utilising the compound and a sterile vehicle, water being preferred.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • agents such as local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilised powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • the composition may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient.
  • the dosage as employed for adult human treatment will preferably range from 100 to 10000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day.
  • the antibiotic compound according to the present inventio may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics and/or ⁇ -lactamase inhibitor may be employed.
  • compositions also comprise a compound of formula (VIII) or a pharmaceutically acceptable salt or ester thereof:
  • A is hydroxyl, substituted hydroxyl, thiol, substituted thiol, amino, mono- or di-hydrocarbyl substituted amino, or mono- or di-acylamino.
  • a further advantageous composition comprises an antibiotic compound according to the invention together with a ⁇ -lactamase inhibitor of formula (IX) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof:
  • ⁇ -lactamase inhibitors include 6 ⁇ -bromopenicillanic acid and salts and in vivo hydrolysable esters and 6 ⁇ -iodo ⁇ enicillanic acid and salts and in vivo hydrolysable esters thereof.
  • compositions of this invention comprising a ⁇ -lactamase inhibitor are formulated in conventional manner.
  • the present invention also includes a method of treating bacterial infections in humans and animals which comprises the administration of a therapeutically effective amount of an antibiotic compound of this invention.
  • the antibiotic compounds of the present invention are active against a broad range of gram positive and gram negative bacteria, in particular they are useful for treatment of respiratory tract and urinary tract infections in humans and mastitis in cattle.
  • a particular advantage of the antibacterially active compounds of this invention is their stability to ⁇ -lactamase enzymes and they are therefore effective against ⁇ -lactamase producing organisms.
  • the present invention further provides a process for the preparation of a compound of formula (I) which process comprises formylating a compound of formula (X):
  • R 1 , R 3 , R 7 and Y are as defined with respect to formula (I);
  • R 18 is a readily removable carboxy protecting group; and thereafter, if necessary, carrying out one or more of the following steps: (i) converting a group R 18 to a group R 2 ;
  • Suitable formylating agents include mixed anhydrides such as formic acetic anhydride.
  • the reaction may suitably be carried out in a temperature in the range -50°C to 30oC in aprotic solvent such as, for example, dichloromethane, chloroform, dimethylformamide, tetrahydrofuran, hexamethylphosphoramide, or dimethylsulphoxide, in the presence of a tertiary base.
  • a preferred tertiary base employed in the reaction is a base of the pyridine type, such as pyridine, lutidine or picoline.
  • R 19 is C 1-6 alkyl, aryl or benzyl; with anhydrous ammonia , an ammonium salt or an amine of the formula (XII)
  • R 20 is a removable protecting group such as benzyl; in the presence of a metal ion such as mercury, silver, thallium, lead or copper and thereafter if necessary removing any protecting group to form the compound of formula (X).
  • Suitable examples of the alkyl group for R 19 include C 1-6 alkyl groups such as methyl, ethyl, n-, or iso-propyl, and n-, sec-; iso-, or tert-butyl groups.
  • a preferred alkyl group for R 19 is methyl.
  • Suitable examples of the aryl group R 19 include phenyl, optionally substituted with C 1-6 alkyl, C 1-6 alkoxy, halogen, or nitro.
  • Preferred aryl groups for R 19 include phenyl, o-, m- or p-methylphenyl, o-, m- or p-nitrophenyl, in particular p-methylphenyl.
  • Suitable solvents in which the reaction may be performed include for example, diethylether, tetrahydrofuran, dimethylformamide, methanol and hexamethylphosphoramide.
  • the reactions are generally carried out under an inert atmosphere and at moderate to low temperatures ie in the range -100oC to 30°C.
  • the course of the reaction may be followed by conventional methods such as thin layer chromatography and terminated when an optimum quantity of product is present in the reaction mixture.
  • the preferred metal ion for use in the above process is the mercuric ion, aptly in the form of mercuric acetate.
  • R 1 , R 3 , R 7 , R 18 and R 19 are as hereinbefore defined;
  • Hal is chloro or bromo, with anhydrous ammonia, an ammonium salt or an amine of formula (XII) as hereinbefore defined and thereafter if necessary removing any protecting group to form the compound of formula (X).
  • the compounds of the formula (XIII) may be prepared by the reaction of a compound of the formula (XI) as hereinbefore defined, with a halogenating agent such as chlorine or bromine in an inert solvent, for example dichloromethane, at a depressed temperature such as -80°C to -30°C.
  • a further method of preparation of the compounds of the formula (X) comprises the reaction of a compound of the formula (XIV):
  • R 1 , R 3 , R 7 , R 18 and R 19 are as hereinbefore defined; with anhydrous ammonia, an ammonium salt or an amine of the formula (XII) as hereinbefore defined and thereafter if necessary removing any protecting group to form the compound of the formula (X).
  • reaction is performed at a non-extreme temperature for example 0°C - 60°C, normally 10°C - 40°C and preferably ambient.
  • the reaction is conveniently performed in an aprotic solvent such as tetrahydrofuran or dioxan.
  • the compounds of the formula (XIV) may be prepared by the oxidation of a compound of the formula (XI) as hereinbefore defined. Such oxidation may conveniently performed in conventional manner, for example using a per-acid such as peracetic acid or m-chloroperbenzoic acid, suitably at an ambient or depressed temperature. Suitable solvents for such a sulphoxidation include ethylacetate, chloroform, dichloromethane, dioxan and tetrahydrofuran.
  • R 18 , R 19 and Y are as defined hereinbefore.
  • Compounds of the formula (XV) may be prepared by methods known or analogous to those known for the preparation of 7 ⁇ -substituted-thio cephalosporins and 6 ⁇ -substituted-thio penicillins.
  • the compound of formula (XV) is prepared by reacting the amino compound (A) with an aldehyde of formula Ar-CHO wherein Ar is an aryl group to form the Schiff base (B).
  • the Schiff base (B) is reacted with a base to form an anion which is treated with a thiosulphonate of formula:
  • R 18 and R 19 are as defined hereinbefore above with a tri(alkyl)phosphine or tri(aryl)phos ⁇ hine, followed by treatment with an acid catalyst such as silica gel.
  • an acid catalyst such as silica gel.
  • the compounds of formula (I) may also be prepared by reacting a compound of formula (XVII):
  • R 1 , R 3 and R 7 are as defined with respect to formula (I) and wherein any reactive groups therein may be protected; and thereafter, if necessary, carrying out one or more of the following steps:
  • Suitable groups which permit acylation to take place and which are optionally present on the amino group of the starting material of the formula (XVII) include N-silyl, N-stannyl and N-phosphorus groups, for example trialkylsilyl groups such as trimethylsilyl, trialkyltin groups such as tri-n-butyltin, groups of formula -P.R a R b wherein R a is an alkyl, haloalkyl, aryl, aralkyl, alkoxy, haloalkyl, aryl, aralkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy or dialkylamino group, R b is the same as R a or is halogen or R a and R b together form a ring; suitable such phosphorus groups being -P(OC 2 H 5 ) 2 , -P(C 2 H 5 ) 2 ,
  • the carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular R 2 group, for example, acid - and base catalysed hydrolysis, or by enzymically - catalysed hydrolysis, or by hydrogenolysis.
  • Suitable carboxyl-protecting derivatives for th0 group -CO 2 R 2 in formula (XVII) include salts and ester derivatives of the carboxylic acid as described hereinbefore with reference to formula (I).
  • a reactive N-acylating derivative of the acid (XVIII) is employed in the above process.
  • the choice of reactive derivative will of course be influenced by the chemical nature of the substituents of the acid.
  • Suitable N-acylating derivatives include an acid halide, preferably the acid chloride or bromide.
  • Acylation with an acid halide may be affected in the presence of an acid binding agent for example, tertiary amine (such as triethylamine, pyridine or dimethylaniline), an inorganic base (such as calcium carbonate or sodium bicarbonate) or an oxirane, which binds hydrogen halide liberated in the acylation reaction.
  • the oxirane is preferably a (C 1-6 )1,2-alkylene oxide - such as ethylene oxide or propylene oxide.
  • the acylation reaction using an acid halide may be carried out at a temperature in the range -50oC to +50oC, preferably -20oC to +20oC, in aqueous or non-aqueous media such as water, acetone, tetrahydrofuran, ethyl acetate, dimethylacetamide, dimethylformamide, acetonitrile, dichloromethane, 1,2-dichloroethane, or mixtures thereof.
  • the reaction may be carried out in an unstable emulsion of water-immiscible solvent, especially an aliphatic ester or ketone, such as methyl isobutyl ketone or butyl acetate.
  • the acid halide may be prepared by reacting the acid (XVIII) or a salt thereof with a halogenating (eg chlorinating or brominating) agent such as phosphorus pentachloride, thionyl chloride or oxalyl chloride.
  • a halogenating agent such as phosphorus pentachloride, thionyl chloride or oxalyl chloride.
  • the N-acylating derivative of the acid (XVIII) may be a symmetrical or mixed anhydride.
  • Suitable mixed anhydrides are alkoxyformic anhydrides, or anhydrides with, for example, carbonic acid monoesters, trimethyl acetic acid, thioacetic acid, diphenylacetic acid, benzoic acid, phosphorus acids (such as phosphoric or phosphorous acids) or aliphatic or aromatic sulphonic acids (such as p-toluenesulphonic acid).
  • carbonic acid monoesters trimethyl acetic acid, thioacetic acid, diphenylacetic acid, benzoic acid, phosphorus acids (such as phosphoric or phosphorous acids) or aliphatic or aromatic sulphonic acids (such as p-toluenesulphonic acid).
  • phosphorus acids such as phosphoric or phosphorous acids
  • aliphatic or aromatic sulphonic acids such as p-toluenesulphonic acid
  • N-acylating derivatives of acid (XVIII) are the acid azide, or activated esters such as esters with 2-mercapto ⁇ yridine, cyanomethanol, p-nitrophenol, 2,4-dinitrophenol, thiophenol, halophenols, including pentachlorophenol, monomethoxyphenol, N-hydroxy succinimide, or 8-hydroxyquinoline; or amides such as N-acylsaccharins, N-acylthiazolidin-2-thione or N-acylphthalimides; or an alkylidene iminoester prepared by reaction of the acid (XVIII) with an oxime.
  • esters such as esters with 2-mercapto ⁇ yridine, cyanomethanol, p-nitrophenol, 2,4-dinitrophenol, thiophenol, halophenols, including pentachlorophenol, monomethoxyphenol, N-hydroxy succinimide, or 8-hydroxyquinoline
  • amides such as N-acyls
  • reactive N-acylating derivatives of the acid (XVIII) include the reactive intermediates formed by reaction in situ with a condensing agent such as a carbodiimide, for example, N,N'-diethyl-, dipropyl- or diisopropylcarbodiimide, N,N'-di-cyclohexylcarbodiimide, or N-ethyl-N'-[3-(dimethylamino)propyl]carbodiimide; a suitable carbonyl compound, for example, N,N'-carbonyldiimidazole or N,N'-carbonylditriazole; an isoxazolinium salt, for example, N-ethyl5-phenylisoxazolinium-3-sulphonate or N-t-butyl-5methylisoxazolinium perchlorate; or an N-alkoxycarbonyl 2-alkoxy-1,2-dihydroquinoline, such as N-eth
  • condensing agents include Lewis acids (for example BBr 3 - C 6 H 6 ); or a phosphoric acid condensing agent such as diethylphosphorylcyanide.
  • the condensation reaction is preferably carried out in an organic reaction medium, for example, methylene chloride, dimethylformamide, acetonitrile, alcohol, benzene, dioxan or tetrahydrofuran.
  • R 1 , R 3 , R 9 and R 10 are as hereinbefore defined; thereby affording a compound having a group R 7 of formula (III) as hereinbefore defined.
  • the compounds of formula (III) may also suitably be prepared by reacting a compound of formula (XXI):
  • R 1 , R 3 , R 2 , R 8 and Y are as hereinbefore defined and the ⁇ -amino group is optionally substituted with a group which permits acylation to take place, and any reactive groups may be protected, with an N-acylating derivative of an acid of formula (XXII):
  • R 9 and R 10 are as hereinbefore defined and wherein any reactive groups may be protected; and thereafter, if necessary, carrying out one or more of the following steps: i) removing any carboxyl-protecting group R 2 ; ii) removing any protecting groups on the side-chain group; iii) converting one group Z to a different group Z; iv) converting the product into a salt or in vivo hydrolysable ester thereof.
  • ⁇ -amino group is optionally substituted with a group which permits acylation to take place and any reactive groups may be protected, and R 1 , R 2 and
  • R 3 are as hereinbefore defined with an N-acylating derivative of an acid of formula (XXIV) :
  • R 12 and R 13 are as defined with respect to formula (IV) above and any reactive groups may be protected; and thereafter, if necessary, carrying out one or more of the following steps: i) removing any carboxyl-protecting group R 2 ; ii) removing any protecting groups on the side-chain group; iii) converting the product into a salt or in vivo hydrolysable ester thereof.
  • the compounds of formula (XXI) herein may be prepared by reacting a compound of formula (XVII) with an N-acylating derivative of an acid of formula (XXV) :
  • R 21 is an amino-protecting group and thereafter removing protecting group R 21 .
  • Suitable amino protecting groups R 21 include alkoxycarbonyl groups such as, for example, 4-nitrobenzyloxycarbonyl and trichloroethyloxycarbonyl.
  • R 2 is as defined hereinbefore with an N-acylating derivative of an acid of formula (XXV) as hereinbefore defined.
  • the intermediate compound of formula (XVII) as hereinbefore defined may suitably be prepared by formylating a compound of formula (XXX) :
  • R 18 , R 21 and Y are as hereinbefore defined and thereafter removing the protecting group R 21 and if necessary, converting a group R 18 to a group R 2 .
  • Suitable formylating agents and reaction conditions are as hereinbefore defined.
  • R 22 is an acyloxy group -CO 2 R 2 must be in the free acid form or a salt thereof.
  • Suitable leaving groups R 22 include halogen such as iodide or bromide or an acyloxy groups such as, for example the acetyloxy group.
  • the thiol HetSH may be reacted as the free compound or a salt with an alkali metal such as sodium or potassium.
  • This reaction is desirably conducted in a solvent.
  • a solvent for example, use can be made of water, or organic solvents inert to the starting compounds, such as dimethylformamide, dimethylacetamide, dioxane, acetone, alcohol, 1,2-dichloroethane, acetonitrile, dimethylsulfoxide or tetrahydrofuran, or mixtures thereof.
  • the reaction temperature and time depend, among other factors, upon the starting compounds and solvent to be employed but generally the reaction is carried out at a selected temperature within the range of 0 to 100°C for a selected time of a few hours to several days.
  • the reaction is desirably conducted between pH 3 and 7.
  • R 1 , R 2 , R 3 , R 7 , R P , R q and Y 1 are as defined hereinbefore may suitably be prepared by reacting a compound of formula (XXXII) as hereinbefore defined with the appropriately substituted pyridine.
  • reaction with the pyridine is carried out in a polar solvent such as water, and in the presence of a catalyst such as an alkali metal thiocyanate or an alkali metal halide such as, for example sodium iodide.
  • a catalyst such as an alkali metal thiocyanate or an alkali metal halide such as, for example sodium iodide.
  • the antibiotic compounds of the present invention are active against a wide range of gram negative and gram positive organisms including E.coli such as, for example ESS, JT4, JT425 and NCTC 10418; Pseudomonas Spp. such as Ps.aeruginosa for example 10662 and Dalgleish; Serratia marcescens US32; Klebsiella aerogenes A; Enterobacter cloacae N1; P.mirabilis such as, for example C977 and 889; P.morganii; P.rettgeri; B.subtilis; Staph aureus such as, for example Oxford and Russell; N.catarrhalis 1502; Strep faecalis I; ⁇ -Haemolytic Strep CN10.
  • the MIC data included in the following examples is representative of the activity of the compounds of the present invention.
  • Example 1 illustrates the preparation and use of the compounds of the present invention.
  • Benzyl 6 ⁇ -formamido-6 ⁇ -(2,2,2-trichloroethoxycarbonylamino) penicillanate (1.31g, 2.5mMole) was dissolved in tetrahydrofuran (100ml) at room temperature and treated with M. potassium dihydrogen phosphate (25ml) followed by acid washed zinc metal (5g). The resulting pH of the mixture was 3.5 and was maintained below 4.5 by addition of 5M. hydrochloric acid when necessary.
  • Benzyl 6 ⁇ -formamido-6 ⁇ -[D-2-[3,4-(methylenedioxy)phenyl]-2 (4-nitrobenzyloxycarbonylamino)acetamido] penicillanate (0.960g, 1.36mmol) was dissolved in THF (25ml) and water added until the solution almost went cloudy, then 10% palladium on charcoal (0.96g) was added under an inert atmosphere. This mixture was hydrogenated for 2 hour, the catalyst filtered off, and the THF removed in vacuo.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composé de formule (I) ou son sel, dans laquelle R1 et R3 représentent indépendamment un groupe hydrolysable in vivo, ou R1 et R3 forment ensemble un groupe hydrolysable in vivo, à condition que R1 et R3 ne représentent pas tous deux un alkyle-carbonyle C1-6; R7 est un hydroxyle, un groupe acide carboxylique ou un alkyle ou phényle inférieur, l'ester de tolyle ou d'indanyle de ceux-ci, un groupe amino ou un groupe amino substitué; R2 représente l'hydrogène ou un groupe de protection carboxyle pouvant être aisément enlevé; Y représente (II), où Y1 représente l'oxygène, le soufre ou -CH2- et Z représente l'hydrogène, l'halogène, ou un groupe organique tel qu'un alkoxy C1-4, -CH2Q ou -CH=CH-Q dans lesquels Q représente l'hydrogène, l'halogène, un groupe hydroxy, mercapto, cyano, carboxy, carbamoyloxy, un ester carboxylique, un alkoxy C1-4, un acyloxy, un aryle, un hétérocyclyle lié par un carbone, un groupe hétérocyclylthio ou un azote contenant un groupe hétérocyclique lié par l'azote.
PCT/GB1984/000010 1983-01-21 1984-01-19 AGENTS ANTIBACTERIENS DE beta-LACTAME WO1984002911A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB838301694A GB8301694D0 (en) 1983-01-21 1983-01-21 Beta-lactam antibacterial agents

Publications (1)

Publication Number Publication Date
WO1984002911A1 true WO1984002911A1 (fr) 1984-08-02

Family

ID=10536717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1984/000010 WO1984002911A1 (fr) 1983-01-21 1984-01-19 AGENTS ANTIBACTERIENS DE beta-LACTAME

Country Status (4)

Country Link
EP (1) EP0131611A1 (fr)
JP (1) JPS60500497A (fr)
GB (1) GB8301694D0 (fr)
WO (1) WO1984002911A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910772A (en) * 1987-08-16 1990-03-20 Yeda Research & Development Co. Ltd. Video scrambling apparatus and method based on space filling curves
WO2014165126A3 (fr) * 2013-03-12 2015-11-05 Gladius Pharmaceuticals Corporation 3-styryl-céphalosporines dérivées
US10239890B2 (en) 2007-10-09 2019-03-26 Gladius Pharmaceuticals Corporation Broad spectrum beta-lactamase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0066373A1 (fr) * 1981-05-22 1982-12-08 Beecham Group Plc Dérivés de bêta-lactame, procédé de préparation et les compositions les contenant
EP0071395A1 (fr) * 1981-07-25 1983-02-09 Beecham Group Plc Agents antibactériens bêta-lactamiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0066373A1 (fr) * 1981-05-22 1982-12-08 Beecham Group Plc Dérivés de bêta-lactame, procédé de préparation et les compositions les contenant
EP0071395A1 (fr) * 1981-07-25 1983-02-09 Beecham Group Plc Agents antibactériens bêta-lactamiques

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910772A (en) * 1987-08-16 1990-03-20 Yeda Research & Development Co. Ltd. Video scrambling apparatus and method based on space filling curves
US10239890B2 (en) 2007-10-09 2019-03-26 Gladius Pharmaceuticals Corporation Broad spectrum beta-lactamase inhibitors
WO2014165126A3 (fr) * 2013-03-12 2015-11-05 Gladius Pharmaceuticals Corporation 3-styryl-céphalosporines dérivées
US9975905B2 (en) 2013-03-12 2018-05-22 Gladius Pharmaceuticals Corporation Derivatized 3-styryl-cephalosporins
US11028103B2 (en) 2013-03-12 2021-06-08 Gladius Pharmaceuticals Corporation Derivatized 3-styryl-cephalosporins

Also Published As

Publication number Publication date
EP0131611A1 (fr) 1985-01-23
JPS60500497A (ja) 1985-04-11
GB8301694D0 (en) 1983-02-23

Similar Documents

Publication Publication Date Title
EP0071395B1 (fr) Agents antibactériens bêta-lactamiques
EP0114752B1 (fr) Agents antibactériens dérivés de bêta-lactame
US4820701A (en) Penam derivatives
EP0131174B1 (fr) Antibiotiques bêta-lactame dérivés de la phénylglycine substituée
EP0114750A2 (fr) Bêta-lactame comme agents antibactériens
WO1984002911A1 (fr) AGENTS ANTIBACTERIENS DE beta-LACTAME
EP0115405B1 (fr) Procédé de préparation de dérivés de bêta-lactame
US4308259A (en) Penicillin derivatives
US4661480A (en) Formamido oxacephems
US4416883A (en) Penicillin derivatives
US4349551A (en) Penicillin derivatives and compositions containing them
EP0066373B1 (fr) Dérivés de bêta-lactame, procédé de préparation et les compositions les contenant
US4540688A (en) β-Lactam antibiotics
US4835150A (en) Cephem compounds
EP0084948B1 (fr) Dérivés de pénicilline
US4394375A (en) Cephalosporin derivatives, and compositions containing them
CA1202959A (fr) Methode de preparation de derives de penam
GB1572201A (en) Cephalosporins
EP0167011A2 (fr) Dérivés de bêta-lactame, leurs intermédiaires, leur application à la préparation de bêta-lactames ayant un groupe dicétopipérazine
EP0166377A1 (fr) Procédé pour la préparation de dérivés de bêta-lactame et intermédiaires
IE53889B1 (en) Beta-lactam antibacterial agents
EP0389178A2 (fr) Dérivés d'acide acrylamidopénicillanique

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): GB JP US

AL Designated countries for regional patents

Designated state(s): CH DE FR GB NL

WWE Wipo information: entry into national phase

Ref document number: 1984900522

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1984900522

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1984900522

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1984900522

Country of ref document: EP